|
Deca and Dianabol
Deca durabolin (nandrolene decanoate), or simply deca, is a great anabolic steroid that is used to gain strength and add mass. It is also a medically favorable steroid since it can be used to reduce joint problems and helps on osteoporosis. It increases calcium and potassium in the body which aids muscle growth and function. This is so because these ions help in release of insulin and transmitting nerve signals. The former helps in increasing the body mass and the latter effect increases strength. It can also be used during radiotherapy of patients with laryngeal cancer since it increases the sensitivity of laryngeal cells to radiotherapy. It can also be used to treat anemia associated with kidney failure.
Patients with breast cancer, diabetes, liver maladies, cardiovascular disease and any kidney problems need to verify first if deca usage is safe for them. Pregnant and nursing women should avoid using it. Also people on growth hormone medication, finasteride or or warfarin should not use deca durabolin because it tends to interact with it.
Deca and dianabol are used together in a mass cycle to elicit maximum muscle gain. Deca or nandrolone decanoate is administered as an intra muscular injection. The drug should also be kept away from bright light such as sunlight and should not be exposed to below freezing temperatures either. The best temperature for storing it is from 15 to 300C.
Nandrolene decanoate is banned in the US and also by the athletic organizations such as the International Olympic Committees for use in athletes. However, its medical benefits give it an advantage. Deca and dianabol usage together is also quite safe as both of them stack well and have few side effects though in excessive amounts, decadurabolin may produce a number of side effects including acne, hair loss, difficulty in passing urine and even impotence in men.
If things go wrong, depression, gastrointestinal discomfort, bleeding and weight gain may occur. In such a case, a physician should be immediately consulted. In children it may promote bone maturation but may fail to increase linear extension of the bone causing them to have a small stature. It may also lead to irregular growth and sexual development in children. If consumed by pregnant women, it may cause masculinization of the fetus.
For therapeutic uses, usually 4 mg of the steroid are prescribed to be taken orally. Doses may be higher if the purpose of use is loss of fat or building muscles. Hemoglobin and serum lipids should be periodically monitored during use.
Articles:
- Cegedim Strategic Data (CSD) Tracks Pharmaceutical Companies' Print Advertising Investments
- Rate of Decline in Print
Advertising Investments Slows to 4% for 12 Months Ending September
2011 Across Ten Key Markets
PARIS--(Marketwire - Feb 6,
2012) - Cegedim Strategic Data (CSD)
(www.cegedimstrategicdata.com), leading provider of...
- Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia
- Company Confirms Plans to File NDA for Suvorexant in
2012
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb 6, 2012 - Merck
(NYSE:MRK), known as MSD outside the United States and Canada,
today provided an update on the development program for...
- Anacor Pharmaceuticals Announces That Its Partner GSK Has Voluntarily Paused Enrollment of Ongoing GSK ?052 Phase 1 and 2 Clinical Trials
- PALO ALTO, Calif.--(BUSINESS WIRE)--Feb 6, 2012 - Anacor
Pharmaceuticals (NASDAQ:ANAC) announced today that its partner
GlaxoSmithKline (GSK) has voluntarily paused enrollment in its
current clinical trials of GSK2251052 (GSK ˜052) due to...
- Astellas Pharma Inc.: Reorganization of Astellas?Global Management Structure
- February 6, 2012
Astellas Pharma Inc.: Reorganization of Astellas’Global
Management Structure
Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO:
Yoshihiko Hatanaka, “Astellas”) announced that it will
implement revisions...
- Five Years After HPV Vaccine Law, Virginia Remains Split
- Five Years After HPV Vaccine Law, State Remains Split [Virginian
- Pilot]
From Virginian - Pilot (February 5, 2012)
By Elizabeth Simpson |
The Virginian-Pilot
Tonya McKinney was so intent on her daughter receiving the human
papillomavirus vaccine...
- Pharma cos need to compensate clinical trial victims, rules govt
- Pharma cos need to compensate
clinical trial victims, rules govt [Financial Express
(India)]
From Financial Express (India)
(February 3, 2012)
The government has made it mandatory for pharmaceutical companies
sponsoring clinical trials in the...
- Cardinal Health Statement Regarding Temporary Restraining Order to Avoid Disruption in Controlled Medicine Shipments From Florida
-
DUBLIN, Ohio, Feb. 3, 2012 /PRNewswire/ -- Today Cardinal Health
was granted a temporary restraining order against the Drug
Enforcement Administration's (DEA) immediate suspension order of
its Lakeland, Fla. DEA...
- Cardinal Health Inc. Seeks Restraining Order to Avoid Disruption in Controlled Medicine Shipments from Florida
- DUBLIN, Ohio, Feb. 3, 2012 /PRNewswire/ -- Cardinal Health, one
of the nation's largest health care distributors, today said it
will vigorously contest the Drug Enforcement Administration's (DEA)
immediate suspension of its license to distribute...
- Montreal Pharma Research Cluster Threatened Again As AstraZeneca Closes Lab
- From Canadian Press DataFile
(February 2, 2012)
By Ross Marowits
MONTREAL -- Montreal’s
status as a pharmaceutical research centre is under further threat
as global giants adjust to the loss of patent protection for
blockbuster drugs and...
- Federal Court Dismisses Whistleblower Lawsuit Against Millennium Laboratories
- Millennium Leads Industry Initiative and Calls on Other
Laboratories to Implement Higher Compliance Standards; Funds a
National Summit Chaired by Dr. Richard Payne, Professor of Medicine
and Divinity at Duke University for Establishment of Industry...
- Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
- CAMBRIDGE, Mass., Feb. 3, 2012
/PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a
biopharmaceutical company engaged in the discovery and development
of drugs for the treatment of human viral diseases, today announced
that it has received...
- Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc.
- NEW YORK--(BUSINESS WIRE)--Feb 3, 2012 - Bristol-Myers Squibb
Company (NYSE: BMY) announced today that the waiting period under
the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended
(HSR) for its tender offer for Inhibitex, Inc....
- Gilead Sciences Announces Fourth Quarter and Full Year 2011 Financial Results
- - Fourth Quarter Product
Sales of $2.13 Billion, up 11% Year over Year -
- Full Year 2011 Product
Sales of $8.10 Billion, up 10% over 2010 -
- Full Year 2011 Non-GAAP
EPS of $3.86, up 5% over 2010 -
- Full Year 2011 Operating
Cash Flows of $3.64...
- Drug maker Alkermes Fiscal 3Q Loss Widens
- From Associated Press (February
2, 2012)
Drug maker Alkermes PLC’s
fiscal third-quarter loss widened as operating expenses ballooned
compared to the previous year’s quarter, before the company
had completed its acquisition of Elan...
- Gilead Sciences 4Q Profit Rises on HIV Drug Sales
- From Associated Press (February
2, 2012)
FOSTER CITY, Calif. -- Gilead Sciences Inc.'s profit grew 6 percent
in the fourth quarter on greater sales of its HIV drugs including
Atripla.
Gilead said Thursday that its
profit rose to $665.1 million, or...
- Vertex Posts 4Q Profit on Growing Incivek Sales
- From Associated Press (February 2,
2012)
CAMBRIDGE, Mass. -- Drugmaker
Vertex Pharmaceuticals Inc. said Thursday it turned a profit in the
fourth quarter on sales of its hepatitis C pill Incivek, which was
approved in May.
Vertex reported a profit...
- Merck KGaA and Threshold Announce Global Agreement to Co-Develop and Commercialize Phase III Hypoxia-Targeted Drug TH-302
- Phase III soft tissue sarcoma trial
ongoing; randomized Phase II pancreatic cancer trial expected to
report in February 2012
Deal provides Threshold with an
upfront payment of ‚¬ 19 million ($25 million), plus
further potential milestones...
- Mikulski Bill Would Speed Approval of New Drugs By FDA
- Mikulski bill would speed approval of new drugs by FDA [The
Baltimore Sun]
From Baltimore Sun (MD) (February 2, 2012)
Feb. 02--WASHINGTON -- Drugs for chronic conditions such as
Alzheimer's disease and diabetes would move through the Food and
Drug...
- Allergan Reports Fourth Quarter 2011 Operating Results
- Board of Directors Declares Fourth
Quarter Dividend
IRVINE, Calif.--(BUSINESS WIRE)--Feb 2, 2012 - Allergan, Inc.
(NYSE: AGN) today announced operating results for the quarter ended
December 31, 2011. Allergan also announced that its Board...
- Are We Sure Our Drugs Are Safe?
- Are We Sure Our Drugs Are Safe? [St. Joseph News-Press (MO)]
From St. Joseph News-Press (MO) (February 1, 2012)
(CNN) -- When Americans pick up their prescriptions from the
pharmacy or reach for a prescription bottle from their medicine
cabinet,...
- Novo Nordisk increased operating profit by 18% in 2011
- Sales growth of 9% driven by Victoza®, NovoRapid® and
Levemir®
* Sales increased by 11% in local currencies
and by 9% in Danish kroner.
o Sales of
modern insulins...
- Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
- 2011 Full-Year Non-GAAP EPS of $3.77,
Excluding Certain Items; GAAP EPS of $2.02; Fourth-Quarter Non-GAAP
EPS of $0.97, Excluding Certain Items; GAAP EPS of $0.49
2011 Full-Year Worldwide Sales Grew
Four Percent to $48.0 Billion, Including Two...
- AstraZeneca?s New Restructuring Initiatives to Drive Productivity and Support Innovation
- Thursday, 2 February 2012
In conjunction with the publication of its full year 2011
results earlier today, AstraZeneca announced new restructuring
initiatives designed to improve productivity and strengthen the
company’s commercial, operations...
- Agennix AG Halts Phase II/III OASIS Trial in Severe Sepsis
- PLANEGG, GERMANY and MUNICH, GERMANY--(Marketwire - Feb 2, 2012)
- Agennix AG (FRANKFURT: AGX) (XETRA: AGX) (ISIN DE000A1A6XX4)
announced that, upon the recommendation of the study Data Safety
Monitoring Board (DSMB), the Company has stopped further...
- Independent Survey of US Oncologists by National Analysts Worldwide Finds Drug Shortages and Escalating Costs Result in Grave Health Consequences
- Nearly half of surveyed oncologists saw tumors recur and
patients die sooner due to drug shortages; 73 percent substituted
sub-optimal care due to patient inability to afford drug
co-payments
PHILADELPHIA--(BUSINESS WIRE)--Feb 1, 2012 - A...
- Which Pharma company is leading the charge in Productive Innovation for 2012?
- IDEA Pharma has launched the second annual Productive Innovation
Index (PII), ranking 21 global pharmaceutical companies for their
ability to add value to, and derive value from, molecules in
pre-launch.
The word “innovation” is often...
- Pfizer EVP Among Obama 'Top Money Bundlers'
- Obama releases list of top money 'bundlers'
From Associated Press (February 1, 2012)
WASHINGTON -- President Barack Obama's re-election campaign
identified its top fundraisers on Tuesday, including 61 people who
each raised at least half a million...
- D&R Acquires LATHIAN to Create Leading Multichannel Marketing Agency
- New Combined Entity Delivers Strategic Multichannel Marketing
Services Under One Roof for Pharmaceutical Companies to Increase
Brand Performance at Any Stage of their Product Lifecycle
SHREWSBURY, N.J. & LAKE FOREST, Calif.--(BUSINESS...
- Study: E-Prescribing Shown to Improve Outcomes and Save U.S. Healthcare System Billions of Dollars
- ARLINGTON, VA -- (MARKET WIRE) -- 02/01/12 -- Surescripts, the
nation's e-prescription network, today announced study findings
from de-identified data that link e-prescribing to a significant
increase in first-fill medication adherence. Poor...
- Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases
- DUBLIN and RICHMOND, California, February 1, 2012 /PRNewswire/
--
- Partnership in DNA-binding technology has potential to provide
both companies growth through innovation of new therapies for
people with serious diseases
Shire plc (LSE: SHP,...
- Roche in 2011: Strong results and positive outlook
- Group sales rise 2% 1 (-10% in Swiss francs; +6% in US dollars),
excluding Tamiflu.
Significant foreign exchange impact of –12 percentage points
due to appreciation of the Swiss franc; overall Group sales at 42.5
billion Swiss...
- UCB and Astellas Announce Agreement to Jointly Develop and Commercialize Cimzia (Certolizumab Pegol) in Japan
- Astellas and UCB partner to bring certolizumab pegol to
rheumatoid arthritis patients in Japan
UCB files certolizumab pegol for marketing authorisation with
the Japanese Ministry of Health, Labour and Welfare
Tokyo, Japan and Brussels, Belgium, 1st...
- Pfizer Announces Voluntary Nationwide Recall Of Lo/Ovral-28 And Norgestrel/Ethinyl Estradiol Tablets Due To Possibility Of Inexact Tablet Counts Or Out Of Sequence Tablets
- NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it
has voluntarily recalled 14 lots of Lo/Ovral-28 (norgestrel
and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl
Estradiol Tablets (generic)for customers in the U.S....
- Dendreon Announces CEO and Chairman Succession Plan
- John H. Johnson Elected President, Chief Executive Officer
and Chairman-Elect, Dr. Mitchell H. Gold Elected Executive
Chairman
Company to Hold Conference Call Today at 9:00 a.m. ET/6:00
a.m. PT
SEATTLE--(BUSINESS WIRE)--Feb 1, 2012 - February 1,...
- Roche Nominates Its Directors to Illumina Board
- From Associated Press (January 31, 2012)
SAN DIEGO -- Swiss drugmaker Roche said Tuesday that it plans to
nominate a slate of directors to the board of Illumina Inc., a
diagnostics company Roche is trying to buy.
On Friday Roche went public with an...
- Mannkind Falls on Stock and Debt Offerings
- From Associated Press (February 1, 2012)
VALENCIA, Calif. -- Diabetes drug developer MannKind Corp. said
Tuesday it plans to offer $50 million in stock and as much as $161
million in debt.
MannKind said it intends to sell units made up of one share...
- Sigma-Aldrich Completes Acquisition of BioReliance
-
ST. LOUIS, Jan. 31, 2012 /PRNewswire/ -- From: Rakesh Sachdev,
President and CEO:
Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science
and High Technology company, announced it has completed its
acquisition of ...
- Monthly Roundup - January 2012
- Bydureon Approved: First Once-A-Week Treatment for Type 2 Diabetes
Amylin Pharmaceuticals received FDA-approval of Bydureon (exenatide extended-release for injectable suspension), a once-a-week, 2 mg injection used in conjunction with diet and...
- Roche to Nominate Slate of Independent Directors for Election at Illumina, Inc.'s 2012 Annual Meeting
- Election of director nominees and approval of other proposals
would result in Roche-nominated directors comprising majority of
the Board
BASEL, Switzerland--(BUSINESS WIRE)--Jan 31, 2012 - Roche (SIX:
RO, ROG; OTCQX: RHHBY) announced today that it...
- Orexo?s Drug Discovery Collaboration Terminated and OX-CLI/OX-ESI Projects End
- Uppsala – January 31, 2012 - Orexo AB and Janssen
Pharmaceuticals, Inc., formerly Ortho-McNeil-Janssen
Pharmaceuticals, Inc. and Janssen Pharmaceutica NV ("Janssen"),
have decided to end their research collaboration and license
agreement...
|
